AMRX vs PAHC vs TEVA vs ELAN

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 0x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Teva Pharmaceutical Industries Limited (TEVA) is the cheapest at 30.

0x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Amneal Pharmaceuticals, Inc. is actually cheaper at 13. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.

2%, compared to -27. 0% for Elanco Animal Health Incorporated (ELAN). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus AMRX's -54. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Teva Pharmaceutical Industries Limited (TEVA) is the lower-risk stock at 1.

13β versus Elanco Animal Health Incorporated's 1. 42β — meaning ELAN is approximately 26% more volatile than TEVA relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.

2% net margin versus -4. 9% for Elanco Animal Health Incorporated — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amneal Pharmaceuticals, Inc.

(AMRX) trades at 13. 8x forward P/E versus 23. 3x for Elanco Animal Health Incorporated — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMRX: 23. 9% to $17. 00.

In this comparison, PAHC (1.

1% yield) pays a dividend. AMRX, TEVA, ELAN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +128. 6% 10Y return). Both have compounded well over 10 years (PAHC: +128. 6%, ELAN: -33. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMRX is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock; TEVA is a mid-cap quality compounder stock; ELAN is a mid-cap quality compounder stock. PAHC pays a dividend while AMRX, TEVA, ELAN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.